Tag Archives: SCCHN

November, 2018

7 November
Nektar and Pfizer Collaborate to Evaluate Combination of NKTR-214 with Avelumab and Talazoparib or Enzalutamide in Multiple Cancers

SAN FRANCISCO, Nov. 6, 2018 /PRNewswire/ — Nektar Therapeutics (NASDAQ:NKTR) announced that it has entered into an oncology clinical collaboration with Pfizer Inc. (NYSE:PFE) to evaluate several combination regimens in multiple cancer settings, including metastatic castration-resistant prostate cancer (mCRPC) and squamous cell carcinoma of the head and neck (SCCHN). The collaboration will evaluate Nektar’s lead immuno-oncology …
Share

5 June
Incyte’s Epacadostat in Combination with Merck’s Keytruda Demonstrates Clinical Activity Across Multiple Tumors Types

WILMINGTON, Del. & KENILWORTH, N.J.–(BUSINESS WIRE)–Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that updated data from the ongoing Phase 1/2 ECHO-202 trial evaluating epacadostat, Incyte’s selective IDO1 enzyme inhibitor, in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, will be highlighted …
Share

31 March
Incyte, Merck Provide Details on Collaboration of Epacadostat and Keytruda

WILMINGTON, Del. & KENILWORTH, N.J.–(BUSINESS WIRE)–Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced additional details of their clinical development program investigating the combination of epacadostat, Incyte’s investigational oral selective IDO1 enzyme inhibitor, with KEYTRUDA®(pembrolizumab), Merck’s anti-PD-1 therapy, in patients across five …
Share

11 November
Bristol-Myers’ Opdivo Receives FDA Approval for Treatment of Squamous Cell Carcinoma of the Head and Neck

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection, for intravenous use, for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy.1 …
Share

25 April
Bristol-Myers Squibb’s Opdivo Receives Breakthrough Therapy Designation

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Opdivo for the potential indication of recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) after platinum based therapy. The Breakthrough Therapy Designation is …
Share